InsiderTrades.com logo
Richard Klausner net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Richard Klausner Biography and Net Worth

Founder & Board Chair of Lyell Immunopharma

Rick Klausner, M.D., is our founder and current Board Chair and was previously our Chief Executive Officer from September 2018 to July 2020 and Executive Chairman from August 2020 to October 2021. Dr. Klausner is the founder and Chief Scientist of Altos Labs, a private life sciences company. He is the President of the Milky Way Research Foundation and founder and Managing Partner of Milky Way Investments. He was the founder and Director of Juno Therapeutics and the founder and Director of GRAIL. He is the Chairman of Sonoma Biotherapeutics and Co-Founder and Chairman of LifeMine Therapeutics. He is the former Senior Vice President, Chief Medical Officer, and Chief Opportunity Officer of Illumina Corporation. Previously, he was Executive Director for Global Health of the Bill and Melinda Gates Foundation. Dr. Klausner was appointed by Presidents Clinton and Bush as the eleventh Director of the U.S. National Cancer Institute between 1995 and 2001. Dr. Klausner served as chief of the Cell Biology and Metabolism Branch of the National Institute of Child Health and Human Development and a past president of the American Society of Clinical Investigation. He is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, and the National Academy of Medicine. He has served in senior advisory roles to the U.S., Norwegian, Qatari, and Indian governments. Dr. Klausner earned an M.D. from Duke Medical School and a B.S. from Yale University.

What is Richard Klausner's net worth?

The estimated net worth of Richard Klausner is at least $1.07 million as of March 14th, 2025. Dr. Klausner owns 42,168 shares of Lyell Immunopharma stock worth more than $1,073,597 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Klausner may own. Additionally, Dr. Klausner receives an annual salary of $80,000.00 as Founder & Board Chair at Lyell Immunopharma. Learn More about Richard Klausner's net worth.

How old is Richard Klausner?

Dr. Klausner is currently 72 years old. There are 6 older executives and no younger executives at Lyell Immunopharma. Learn More on Richard Klausner's age.

What is Richard Klausner's salary?

As the Founder & Board Chair of Lyell Immunopharma, Inc., Dr. Klausner earns $80,000.00 per year. There are 5 executives that earn more than Dr. Klausner. The highest earning executive at Lyell Immunopharma is Dr. Lynn Seely M.D., Ph.D., President, CEO & Director, who commands a salary of $962,230.00 per year. Learn More on Richard Klausner's salary.

How do I contact Richard Klausner?

The corporate mailing address for Dr. Klausner and other Lyell Immunopharma executives is , , . Lyell Immunopharma can also be reached via phone at 650-695-0677 and via email at [email protected]. Learn More on Richard Klausner's contact information.

Has Richard Klausner been buying or selling shares of Lyell Immunopharma?

Richard Klausner has not been actively trading shares of Lyell Immunopharma over the course of the past ninety days. Most recently, on Friday, March 14th, Richard Klausner bought 7,900 shares of Lyell Immunopharma stock. The stock was acquired at an average cost of $12.00 per share, with a total value of $94,800.00. Following the completion of the transaction, the director now directly owns 42,168 shares of the company's stock, valued at $506,016. Learn More on Richard Klausner's trading history.

Who are Lyell Immunopharma's active insiders?

Lyell Immunopharma's insider roster includes Otis Brawley (Director), Otis Brawley (Director), Richard Klausner (Director), Richard Klausner (Founder & Board Chair), Charles Newton (CFO), Charles Newton (CFO), Sumant Ramachandra (Director), Lynn Seely (President & Chief Executive Officer), and Lynn Seely (CEO). Learn More on Lyell Immunopharma's active insiders.

Are insiders buying or selling shares of Lyell Immunopharma?

In the last twelve months, Lyell Immunopharma insiders bought shares 5 times. They purchased a total of 38,432 shares worth more than $449,508.40. In the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,400 shares worth more than $30,063.50. The most recent insider tranaction occured on November, 10th when CEO Lynn Seely sold 412 shares worth more than $6,637.32. Insiders at Lyell Immunopharma own 22.3% of the company. Learn More about insider trades at Lyell Immunopharma.

Information on this page was last updated on 11/10/2025.

Richard Klausner Insider Trading History at Lyell Immunopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/14/2025Buy7,900$12.00$94,800.0042,168View SEC Filing Icon  
9/23/2022Sell555$128.00$71,040.0049,445View SEC Filing Icon  
See Full Table

Richard Klausner Buying and Selling Activity at Lyell Immunopharma

This chart shows Richard Klausner's buying and selling at Lyell Immunopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Lyell Immunopharma Company Overview

Lyell Immunopharma logo
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $25.46
Low: $21.39
High: $25.59

50 Day Range

MA: $18.18
Low: $12.83
High: $25.46

2 Week Range

Now: $25.46
Low: $7.65
High: $25.59

Volume

93,527 shs

Average Volume

39,594 shs

Market Capitalization

$540.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A